Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
about
The intensive care medicine research agenda on multidrug-resistant bacteria, antibiotics, and stewardship.Sepsis: in search of cure.Prevention of Surgical Site Infections and Biofilms: Pharmacokinetics of Subcutaneous Cefazolin and Metronidazole in a Tumescent Lidocaine Solution.We need to optimize piperacillin-tazobactam dosing in critically ill patients-but how?Clinical outcomes of extended versus intermittent administration of piperacillin/tazobactam for the treatment of hospital-acquired pneumonia: a randomized controlled trial.Using Population Pharmacokinetic Modeling and Monte Carlo Simulations To Determine whether Standard Doses of Piperacillin in Piperacillin-Tazobactam Regimens Are Adequate for the Management of Febrile Neutropenia.Extended infusion of beta-lactam antibiotics: optimizing therapy in critically-ill patients in the era of antimicrobial resistance.High target attainment for β-lactam antibiotics in intensive care unit patients when actual minimum inhibitory concentrations are applied.Challenges and opportunities in the treatment of ventilator-associated pneumonia.The intensive care medicine research agenda on septic shock.Controversies and advances in the management of ventilator associated pneumonia.Hospital Length of Stay Among Patients Receiving Intermittent Versus Prolonged Piperacillin/Tazobactam Infusion in the Intensive Care Units.Meropenem Dosing Based on a Population Pharmacokinetic-Pharmacodynamic Model in Elderly Patients with Infection of the Lower Respiratory Tract.[Therapeutic drug monitoring and individual dosing of antibiotics during sepsis : Modern or just "trendy"?]Update in Critical Care Medicine: Evidence Published in 2016Continuous infusion of beta-lactams: a blissful option for the intensive care unit.Role of renal function in risk assessment of target non-attainment after standard dosing of meropenem in critically ill patients: a prospective observational study.Pharmacokinetics and Pharmacodynamic Target Attainment of Benzylpenicillin in an Adult Severely ill Sub-Saharan African Patient Population.Update on ventilator-associated pneumonia.Therapies for multidrug resistant and extensively drug-resistant non-fermenting gram-negative bacteria causing nosocomial infections: a perilous journey toward 'molecularly targeted' therapy.Continuous Infusion Versus Intermittent Bolus of Beta-Lactams in Critically Ill Patients with Respiratory Infections: A Systematic Review and Meta-analysis.Considerable variation of trough β-lactam concentrations in older adults hospitalized with infection-a prospective observational study.Focus on severe infections.The Japanese Clinical Practice Guidelines for Management of Sepsis and Septic Shock 2016 (J-SSCG 2016).Focus on antimicrobial use in the era of increasing antimicrobial resistance in ICU.Population Pharmacokinetics of Meropenem in Plasma and Subcutis from Patients on Extracorporeal Membrane Oxygenation Treatment.Population Pharmacokinetics of Piperacillin in Sepsis Patients: Should Alternative Dosing Strategies Be Considered?Optimal infusion rate in antimicrobial therapy explosion of evidence in the last five years
P2860
Q30238578-9A3F946D-304B-42D9-8A62-FC4CFC02C26EQ30251753-642FC3A1-0597-4509-9BDE-2F774736A4BBQ30854769-531B2410-5B97-4002-BAE2-D6519745B86DQ36970989-7B59A8CE-64D7-482A-9095-4267418D4FDFQ37642084-3E891429-A958-4608-BD7C-8C0CDA529F1FQ38625059-3567125B-1C72-4BAA-AAC2-13953FC74C97Q38705266-70E129BF-003B-455C-B5CB-D916393D93F2Q38798373-1D7D222B-51A5-4D90-ABAD-B9B05770CA77Q38988630-019F6C5B-BE7B-4B87-ACCB-E7804A670599Q39303486-7F51F14F-0BA2-42A9-A077-95232E8FAAE5Q40054170-6BFC7BE6-BD86-460C-8DE8-FE496DFB28A4Q40219976-2AB3FD26-5B33-4CA2-AE8E-22180F9C5C2AQ40367930-AFF77A6B-9A91-4EA9-914C-28DD2AC72E10Q40541397-B9BBD1A2-DC48-4B0E-B89F-7D3027B008E4Q42181731-98ED82DB-C8A9-4B6C-B97E-7B84E993E6E2Q42331413-3F5AD216-3875-46AF-9AFF-266B53603496Q42654588-B53FB688-C8C6-41F5-AB22-D6090057454AQ46545782-175663EF-FCED-4BFC-817C-14225CEE3267Q47129727-2500947A-0C03-4865-8D24-3A9533D14545Q47661746-99F17D62-AB4A-4B3C-AE42-9B3394F5156DQ47745708-95CC94B5-7F4E-4CDD-98EB-6AA7FD53CEF4Q48144933-F71FBF10-A03B-4F81-A14E-86167A2BDE7BQ48148163-D2D4150A-5B6F-49B7-A81F-CEB64AE80E83Q50052469-FA50ACEC-7492-45B5-A41D-929AA4949EA1Q53791273-DE322C29-6C6A-4D6B-9AF9-1213C6C957FFQ54257517-1D48A3DB-936A-44D1-A511-48D84064EBC4Q54261873-673B83E5-66FD-484B-A8ED-A512104F6E3DQ58795590-EC426962-EE9E-48DB-BC7B-EFCDD18B7139
P2860
Beta-Lactam Infusion in Severe Sepsis (BLISS): a prospective, two-centre, open-labelled randomised controlled trial of continuous versus intermittent beta-lactam infusion in critically ill patients with severe sepsis.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年学术文章
@wuu
2016年学术文章
@zh-cn
2016年学术文章
@zh-hans
2016年学术文章
@zh-my
2016年学术文章
@zh-sg
2016年學術文章
@yue
2016年學術文章
@zh
2016年學術文章
@zh-hant
name
Beta-Lactam Infusion in Severe ...... l patients with severe sepsis.
@en
type
label
Beta-Lactam Infusion in Severe ...... l patients with severe sepsis.
@en
prefLabel
Beta-Lactam Infusion in Severe ...... l patients with severe sepsis.
@en
P2093
P50
P1476
Beta-Lactam Infusion in Severe ...... ll patients with severe sepsis
@en
P2093
Azrin N Abd Rahman
Helmi Sulaiman
Janattul A Jamal
Kang K Wong
Mohd S Hasan
Mohd-Basri Mat-Nor
Steven C Wallis
Vineya Rai
P2888
P304
P356
10.1007/S00134-015-4188-0
P577
2016-01-11T00:00:00Z